DNLI · Denali Therapeutics Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $330.53M | $108.46M | $48.66M | $335.66M | $26.68M | $129.16M | $0 | $0 | |
| $400.72M | $418.78M | $396.44M | $423.88M | $358.73M | $265.35M | $212.62M | $193.38M | $143.18M | $74.46M | $75.7M | |
| $140.72M | $136.56M | $105.44M | $103.35M | $90.48M | $79.06M | $60.33M | $46.48M | $32.35M | $15.68M | $11.73M | |
| — | $11.18M | $7.8M | $16.73M | $10.38M | $8.59M | $8.53M | $7.99M | $7.42M | $3.08M | $1.47M | |
| $547.12M | $555.34M | $501.88M | $527.23M | $449.21M | $344.41M | $272.94M | $239.86M | $175.53M | $90.14M | $87.43M | |
| -$542.7M | -$555.34M | -$487.34M | -$196.7M | -$340.74M | -$295.75M | $62.72M | -$213.18M | -$46.37M | -$90.14M | -$87.43M | |
| — | — | — | -59.51% | -314.16% | -607.78% | 18.69% | -799.1% | -35.9% | — | — | |
| — | -$544.16M | -$479.55M | -$179.97M | -$330.36M | -$287.16M | $71.25M | -$205.19M | -$38.96M | -$87.06M | -$85.96M | |
| — | — | — | $51.51M | $14.77M | $4.6M | $9.24M | $15.22M | $10.13M | $1.96M | $781K | |
| — | $102K | $68K | $30K | $21K | -$575K | $823K | -$351K | $0 | $0 | — | |
| -$511.45M | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -$290.58M | $71.14M | -$197.61M | -$36.24M | -$88.19M | -$86.65M | |
| — | — | — | -43.94% | -300.56% | -597.15% | 21.19% | -740.74% | -28.06% | — | — | |
| -$514.36M | -$513.88M | -$421.4M | -$137.7M | -$330.38M | -$292.84M | $70.54M | -$196.62M | -$36.52M | -$88.18M | -$87.03M | |
| USD/shares | — | -$2.97 | -$2.57 | -$1.06 | -$2.60 | -$2.39 | $0.65 | -$2.07 | -$0.39 | — | — |
| USD/shares | — | -$2.97 | -$2.57 | -$1.06 | -$2.60 | -$2.39 | $0.63 | -$2.07 | -$0.39 | — | — |
| shares | — | 172.65M | 164.47M | 137.37M | 125.53M | 121.52M | 108.97M | 95.61M | 92.62M | 14.96M | 6.42M |
| shares | — | 172.65M | 164.47M | 137.37M | 125.53M | 121.52M | 112.7M | 95.61M | 92.62M | 14.96M | 6.42M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 217 similar-size Biotechnology companies (of 546 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Therapeutics Segment | $0 | $0 | $330,531,000 | $108,463,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Therapeutics Segment | -$555,342,000 | -$487,341,000 | -$196,699,000 | -$340,744,000 |
Operating Margin by Segment (%)
| Component | FY2023 | FY2022 |
|---|---|---|
| Therapeutics Segment | -59.5% | -314.2% |